Want to see SKYE full AI Analyst Report?
Skye Bioscience (SKYE) Ratios
Skye Bioscience Ratios
SKYE's free cash flow for Q2 2026 was $-7.12M. For the 2026 fiscal year, SKYE's free cash flow was increased by $0.00 and operating cash flow was $-7.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 |
| Quick Ratio | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 |
| Cash Ratio | 0.72 | 15.77 | 0.09 | 0.10 | 2.30 |
| Solvency Ratio | -6.66 | -5.70 | -2.67 | -1.60 | -2.13 |
| Operating Cash Flow Ratio | -5.25 | -5.82 | -1.00 | -1.05 | -1.66 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -3.19 | -6.69 | -3.28 |
| Net Current Asset Value | $ 18.80M | $ 66.22M | $ -2.42M | $ -3.18M | $ 5.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.39 | 0.22 | 0.22 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | -2.16 | -0.66 | 0.36 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 1.86 | -1.93 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.41 | 1.07 | -5.60 | -3.03 | 1.68 |
| Debt Service Coverage Ratio | 0.00 | -26.15 | -6.94 | -7.28 | -2.82 |
| Interest Coverage Ratio | 0.00 | -31.20 | -38.33 | -27.59 | -10.22 |
| Debt to Market Cap | 0.00 | 0.00 | 0.23 | 0.21 | 0.09 |
| Interest Debt Per Share | 0.06 | 0.04 | 0.79 | 1.19 | 1.79 |
| Net Debt to EBITDA | 0.10 | 2.69 | -0.09 | -0.04 | 0.89 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.01% | 100.04% | 100.01% | 100.03% | 100.02% |
| EBT Per EBIT | 96.14% | 87.96% | 108.37% | 106.35% | 108.57% |
| Return on Assets (ROA) | -197.52% | -36.51% | -315.27% | -213.82% | -86.47% |
| Return on Equity (ROE) | -279.29% | -38.98% | 1765.85% | 647.65% | -145.33% |
| Return on Capital Employed (ROCE) | -289.25% | -44.13% | 1771.67% | 608.76% | -132.05% |
| Return on Invested Capital (ROIC) | -286.55% | -44.01% | -1398.67% | 1785.59% | -98.09% |
| Return on Tangible Assets | -197.52% | -36.51% | -315.27% | -213.82% | -86.47% |
| Earnings Yield | -188.00% | -25.73% | -197.54% | -219.28% | -40.31% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1026.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1026.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.69 | -0.69 | -1.99 | -5.74 | -3.98 |
| Free Cash Flow Per Share | -8.69 | -0.74 | -1.99 | -5.75 | -4.04 |
| Dividend Paid and CapEx Coverage Ratio | -6822.33 | -15.73 | -1111.73 | -454.17 | -71.26 |
| Capital Expenditure Coverage Ratio | -6822.33 | -15.73 | -1111.73 | -454.17 | -71.26 |
| Operating Cash Flow Coverage Ratio | -157.37 | -55.40 | -3.02 | -6.43 | -3.03 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -144.78% | -25.99% | -73.28% | -143.76% | -31.05% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.53 | -3.88 | -0.51 | -0.46 | -2.48 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.49 | 1.52 | -8.94 | -2.95 | 3.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.69 | -3.85 | -1.36 | -0.70 | -3.22 |
| Price-to-Operating Cash Flow Ratio | -0.69 | -4.09 | -1.37 | -0.70 | -3.27 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.04 | 0.01 | -0.01 | 0.08 |
| Enterprise Value Multiple | -0.44 | -1.40 | -0.61 | -0.51 | -1.85 |
| Enterprise Value | 24.14M | 35.30M | 22.42M | 9.62M | 14.30M |
| EV to EBITDA | -0.44 | -1.40 | -0.61 | -0.51 | -1.85 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.56 | -1.32 | -1.61 | -0.75 | -2.18 |
| EV to Operating Cash Flow | -0.56 | -1.40 | -1.61 | -0.76 | -2.21 |
| Tangible Book Value Per Share | 4.04 | 1.87 | -0.30 | -1.35 | 3.61 |
| Shareholders’ Equity Per Share | 4.04 | 1.87 | -0.30 | -1.35 | 3.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -11.28 | -0.73 | -5.37 | -8.77 | -5.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.04 | 1.02 | 1.04 | 1.10 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.77 | 0.95 | 0.37 | 0.65 | 0.76 |
Currency in USD
